Appili Therapeutics Inc Class A (APLI) Price & Analysis

Compare

26 Followers

APLI Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.01 - C$0.05

Previous CloseN/A

Volume36.33K

Average Volume (3M)64.23K

Market Cap

C$1.82M

Enterprise ValueC$13.05M

Total Cash (Recent Filing)C$1.13M

Total Debt (Recent Filing)C$12.35M

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Nov 13, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding121,266,120

10 Day Avg. Volume90,067

30 Day Avg. Volume64,229

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

Appili Therapeutics Inc Class A News

Appili Therapeutics to present progress on Tularemia vaccine

Appili Therapeutics (APLIF) announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical,...

22d ago

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives

An announcement from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics announced the...

7d ago

Appili Therapeutics to Showcase Tularemia Vaccine at NATO Conference

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has shared an announcement. Appili Therapeutics announced that Dr. Carl...

22d ago

Appili Therapeutics Strengthens Biodefense Partnerships and Advances Drug Development

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an announcement. Appili Therapeutics has reported its financial...

2M ago

Appili Therapeutics, colleagues publish manuscript on ATI-1701 efficacy

Appili Therapeutics (APLIF) announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine...

2M ago

Appili Therapeutics Demonstrates Efficacy of Tularemia Vaccine Candidate

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced a peer-reviewed publication...

2M ago

Appili Therapeutics Advances Infectious Disease Solutions with LIKMEZ Re-launch and Vaccine Developments

The latest announcement is out from Appili Therapeutics Inc Class A ( ($TSE:APLI) ). Appili Therapeutics has re-launched...

3M ago

Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced the formal termination...

4M ago

Appili Therapeutics Faces Termination of Agreement with Aditxt

An announcement from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics announced that...

4M ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt (ADTX) announced that it has determined it is in the best interest of the company and its...

4M ago

ADTX

Appili Therapeutics Advances Tularemia Vaccine Research

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an announcement. Appili Therapeutics announced the publication of...

5M ago

Appili Therapeutics publishes manuscript on emergency response to tularemia

Appili Therapeutics (APLIF) announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a...

5M ago

Appili Therapeutics Secures New Patents for LIKMEZ, Strengthening Market Position

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) just unveiled an update. Appili Therapeutics has announced the granting...

5M ago

Appili Therapeutics granted new patents for LIKMEZ

Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted...

5M ago

APLI FAQ

What was Appili Therapeutics Inc Class A’s price range in the past 12 months?

Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.

What is Appili Therapeutics Inc Class A’s market cap?

Appili Therapeutics Inc Class A’s market cap is C$1.82M.

When is Appili Therapeutics Inc Class A’s upcoming earnings report date?

Appili Therapeutics Inc Class A’s upcoming earnings report date is Nov 13, 2025 which is in 43 days.

How were Appili Therapeutics Inc Class A’s earnings last quarter?

Appili Therapeutics Inc Class A released its earnings results on Aug 14, 2025. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.

Is Appili Therapeutics Inc Class A overvalued?

According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Appili Therapeutics Inc Class A pay dividends?

Appili Therapeutics Inc Class A does not currently pay dividends.

What is Appili Therapeutics Inc Class A’s EPS estimate?

Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Appili Therapeutics Inc Class A have?

Appili Therapeutics Inc Class A has 121,266,120 shares outstanding.

What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?

Appili Therapeutics Inc Class A reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?

Currently, no hedge funds are holding shares in TSE:APLI

Company Description

Appili Therapeutics Inc Class A

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.